Drug Trial Radar · NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Oct 11, 2018
Primary completion
Apr 30, 2027
Study completion Apr 30, 2027
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
Conditions
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- High Risk Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm
- Recurrent Acute Myeloid Leukemia
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Recurrent Myelodysplastic Syndrome
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Acute Myeloid Leukemia
- Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Refractory Myelodysplastic Syndrome
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome
- Very High Risk Myelodysplastic Syndrome
Interventions
Edetate Calcium DisodiumDrug
Given IV
MultivitaminDietary supplement
Given PO
SuccimerDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: At 30 days post-treatment
- Maximum tolerated doses (MTD) of edetate calcium disodium (Ca-EDTA) and succimer (DMSA) (Phase 1 dose escalation)Time frame: Up to the end of cycle 1 (each cycle is 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
M D Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.